Meta Information

ID:testosterone-therapy-women

Name:Testosterone Therapy (Women)

Schema Version:1.5

Alternate Names

• Low-dose Testosterone for Women
• Female Androgen Therapy

Active Compound

testosterone

Intervention Type

therapeutic_agent

Delivery

Route:

topical_skin

Scope:

• systemic

Is Skin Health

False

Regulatory Status

• us:rx_drug
• eu:rx_drug
• ca:rx_drug

Indication

Focus:

symptom_management

Description:

Manages symptoms of Hypoactive Sexual Desire Disorder (HSDD) in postmenopausal women.

Typical Protocol

• Transdermal gels or creams are typically applied daily at very low doses (e.g., 0.5-1.0 mg/day) to the skin, aiming for physiological female levels.
• Subcutaneous pellets containing testosterone may be implanted every 3-6 months, releasing a consistent low dose.

Expected Cost Mean

Low Cost:

50

High Cost:

200

Cost Type:

monthly

Description:

Monthly cost for prescription cream/gel; often not covered by insurance for HSDD.

Summary

Testosterone is an androgen involved in female libido, bone density, and muscle mass. In women, therapeutic use primarily focuses on treating Hypoactive Sexual Desire Disorder (HSDD) in postmenopausal individuals, where it can improve sexual function. Its role as a general healthspan intervention in women, beyond specific deficiency symptoms, lacks robust evidence and is not an approved indication.

Purpose

Manages Hypoactive Sexual Desire Disorder in women, improving sexual function.

Card Summary

Treats HSDD in postmenopausal women; not for general female healthspan.

Drug Class

androgen

Drugs In Class

Empty Array

Impact

Score:

5.5

Justification:

Effective for specific sexual dysfunction symptoms; no broad healthspan benefit.

Evidence

Grade:

A

Score:

8.5

Justification:

Multiple human RCTs support efficacy for HSDD in postmenopausal women.

Safety

Score:

5

Justification:

Risk of virilization and other androgenic side effects if not carefully dosed.

Flags

• Potential for virilization, including hirsutism, acne, voice deepening, and clitoromegaly, especially with supra-physiological dosing.
• Potential adverse effects on lipid profiles (e.g., decreased HDL).
• Not recommended in women with hormone-sensitive cancers (e.g., breast cancer).
• Oral testosterone formulations are associated with significant hepatic toxicity and are generally not used in women.

Verdict

Targeted for HSDD; not a general healthspan intervention for women.